Kazuo Umezawa

Prof. Kazuo Umezawa

Department of Molecular Target Medicine, Aichi Medical University, Nagakute, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AAAkiko Ariga
Akiko Ariga
JNJun-Ichi Namekawa
Jun-Ichi Namekawa
NMNaoki Matsumoto
Naoki Matsumoto
JIJun-Ichiro Inoue
Jun-Ichiro Inoue
KUKazuo Umezawa
Kazuo Umezawa
We previously designed and synthesized an NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti-inflammatory activity in vivo. In the present study we looked into its mechanism of inhibition. DHMEQ inhibited tumor necrosis factor-α (TNF-α)- and 12-O-tetradecanoylphorbol-13-acetate-induced transcriptional activity of NF-κB in human T cell leukemia Jurkat cells. It also inhibited the TNF-α-induced DNA binding of nuclear NF-κB but not the phosphorylation and degradation of IκB. Moreover, DHMEQ inhibited the TNF-α-induced nuclear accumulation of p65, a component of NF-κB. It also inhibited TNF-α-induced nuclear transport of green fluorescent protein-tagged p65. On the other hand, DHMEQ did not inhibit the nuclear transport of Smad2 and large T antigen. Also, it did not inhibit TNF-α-induced activation of JNK but synergistically induced apoptosis with TNF-α in Jurkat cells. Taken together, these data indicate that DHMEQ is a unique inhibitor of NF-κB acting at the level of nuclear translocation.

1 April 2005 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
HTHiroshi Takatsuna
Hiroshi Takatsuna
MAMasataka Asagiri
Masataka Asagiri
TKTakeshi Kubota
Takeshi Kubota
KOKotaro Oka
Kotaro Oka
TOToshihiro Osada
Toshihiro Osada
KUKazuo Umezawa
Kazuo Umezawa
(−)‐DHMEQ, a newly designed NF‐κB inhibitor, inhibited RANKL‐induced osteoclast differentiation in mouse BMMs through downregulation of the induction of NFATc1, an essential transcription factor of osteoclastogenesis. Introduction: Bone destruction is often observed in advanced case of rheumatoid arthritis and neoplastic diseases, including multiple myeloma. Effective and nontoxic chemotherapeutic agents are expected for the suppression of these bone destructions. RANKL induces activation of NF‐κB and osteoclastogenesis in bone marrow‐derived monocyte/macrophage precursor cells (BMMs). Targeted disruption or pharmacological suppression of NF‐κB result in impaired osteoclastogenesis, but how NF‐κB is involved in the regulation of osteoclastogenesis is not known. Materials and Methods: The effect of (−)‐dehydroxymethylepoxyquinomicin [(−)‐DHMEQ] on osteoclast differentiation was studied using a culture system of mouse BMMs stimulated with RANKL and macrophage colony‐stimulating factor. The mechanism of the inhibition was studied by biochemical analysis such as immunoblotting and retroviral transfer experiments. Results: (−)‐DHMEQ strongly inhibited RANKL‐induced NF‐κB activation in BMMs and inhibited RANKL‐induced formation of TRACP+ multinucleated cells. Interestingly, (−)‐DHMEQ specifically inhibited the RANKL‐induced expression of NFATc1 but not the expressions of TRAF6 or c‐fos. Inhibition of osteoclast differentiation by (−)‐DHMEQ was rescued by overexpression of NFATc1, suggesting that the inhibition is not caused by a toxic effect. Moreover, pit formation assays showed that (−)‐DHMEQ also inhibited the bone‐resorbing activity of mature osteoclasts. Conclusion: The inhibition of NF‐κB suppresses osteoclastogenesis by downregulation of NFATc1, suggesting that NFATc1 expression is regulated by NF‐κB in RANKL‐induced osteoclastogenesis. Our results also indicate the possibility of (−)‐DHMEQ becoming a new therapeutic strategy against bone erosion.

22 August 2006 in Cancer Science
Verified
Journal Article
Open access
PDF file
KUKazuo Umezawa
Kazuo Umezawa
NF‐κB is a transcription factor that induces inflammatory cytokines and anti‐apoptotic proteins. NF‐κB is often constitutively activated in human cancers and leukemias, which might increase the malignant character of neoplastic diseases. Therefore, NF‐κB inhibitors might be useful as anticancer agents. Our research team designed a new NF‐κB inhibitor that is based on the structure of the antibiotic epoxyquomicin C isolated from a microorganism. The designed compound, DHMEQ, inhibited the ligand‐induced activation of NF‐κB, and it also inhibited the constitutively activated NF‐κB in cancer cells. DHMEQ is a unique inhibitor of NF‐κB that acts at the level of the nuclear translocation. It inhibited both canonical and non‐canonical NF‐κB activating pathways. It inhibited various carcinomas and leukemias in animal models without any toxicity, and might be useful as an anticancer agent. (Cancer Sci 2006; 97: 990–995)

29 December 1999 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
KUKazuo Umezawa
Kazuo Umezawa
YIYoko Ikeda
Yoko Ikeda
YUYuki Uchihata
Yuki Uchihata
HNHiroshi Naganawa
Hiroshi Naganawa
SKShinichi Kondo
Shinichi Kondo

1 February 2005 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GMGaku Matsumoto
Gaku Matsumoto
JNJun-Ichi Namekawa
Jun-Ichi Namekawa
MMMariko Muta
Mariko Muta
TNTadahiko Nakamura
Tadahiko Nakamura
HBHiroko Bando
Hiroko Bando
KUKazuo Umezawa
Kazuo Umezawa
We previously designed and synthesized the new nuclear factor κB (NF-κB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) derived from the structure of the antibiotic epoxyquinomicin C. We looked into the effect of DHMEQ on cellular phenotypes and tumor growth in mice injected with human breast carcinoma cell line MDA-MB-231 or MCF-7. In estrogen-independent breast adenocarcinoma cell line MDA-MB-231, NF-κB is constitutively activated. The addition of DHMEQ (10 μg/mL) completely inhibited the activated NF-κB for at least 8 hours. On the other hand, NF-κB is not activated in estrogen-dependent MCF-7 cells. In this cell line, DHMEQ completely inhibited the tumor necrosis factor-α-induced activation of NF-κB. DHMEQ did not inhibit the degradation of IκB but inhibited the nuclear translocation of NF-κB by both p65/p50 and RelB/p52 pathways. MDA-MB-231 cells secrete interleukin (IL)-6 and IL-8 without stimulation, and DHMEQ decreased the secretion levels of both cytokines. When MDA-MB-231 or MCF-7 cells were stimulated by tumor necrosis factor-α, the inhibitory effects of DHMEQ were still maintained. I.p. administration of DHMEQ (thrice a week) significantly inhibited the tumor growth of MDA-MB-231 (12 mg/kg) or MCF-7 (4 mg/kg) in severe combined immunodeficiency mice. No toxicity was observed during the experiment, including the loss of body weight. An immunohistological study on resected MCF-7 tumors showed that DHMEQ inhibited angiogenesis and promoted apoptosis. Furthermore, in Adriamycin-resistant MCF-7 cells highly expressing multidrug resistance gene-1, DHMEQ also exhibited the above capability, including down-regulation of IL-8. Thus, DHMEQ might be a potent drug for the treatment of various breast carcinomas by inhibiting the NF-κB activity.

30 September 2005 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
KWKyoko Wakamatsu
Kyoko Wakamatsu
Toshihiro NankiToshihiro Nanki
Toshihiro Nanki
NMNobuyuki Miyasaka
Nobuyuki Miyasaka
KUKazuo Umezawa
Kazuo Umezawa
TKTetsuo Kubota
Tetsuo Kubota
A small cell-permeable compound, dehydroxymethylepoxyquinomicin (DHMEQ), does not inhibit phosphorylation and degradation of IκB (inhibitor of nuclear factor-κB [NF-κB]) but selectively inhibits nuclear translocation of activated NF-κB. This study aimed to demonstrate the antiarthritic effect of this novel inhibitor of the NF-κB pathwayin vivoin a murine arthritis model andin vitroin human synovial cells. Collagen-induced arthritis was induced in mice, and after onset of arthritis the mice were treated with DHMEQ (5 mg/kg body weight per day). Using fibroblast-like synoviocyte (FLS) cell lines established from patients with rheumatoid arthritis (RA), NF-κB activity was examined by electrophoretic mobility shift assays. The expression of molecules involved in RA pathogenesis was determined by RT-PCR, ELISA, and flow cytometry. The proliferative activity of the cells was estimated with tritiated thymidine incorporation. After 14 days of treatment with DHMEQ, mice with collagen-induced arthritis exhibited decreased severity of arthritis, based on the degree of paw swelling, the number of swollen joints, and radiographic and histopathologic scores, compared with the control mice treated with vehicle alone. In RA FLS stimulated with tumor necrosis factor-α, activities of NF-κB components p65 and p50 were inhibited by DHMEQ, leading to suppressed expression of the key inflammatory cytokine IL-6, CC chemokine ligand-2 and -5, matrix metalloproteinase-3, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1. The proliferative activity of the cells was also suppressed. This is the first demonstration of an inhibitor of NF-κB nuclear translocation exhibiting a therapeutic effect on established murine arthritis, and suppression of inflammatory mediators in FLS was thought to be among the mechanisms underlying such an effect.